Cargando…
Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars
Colorectal cancer (CRC) is a leading cause of tumor-related morbidity and mortality worldwide, with mortality most often attributable to metastatic disease. Bevacizumab, a humanized monoclonal antibody targeting vascular endothelial growth factor, has a significant role in the treatment of metastati...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5610666/ https://www.ncbi.nlm.nih.gov/pubmed/28801849 http://dx.doi.org/10.1007/s11523-017-0518-1 |